Literature DB >> 16338459

Tissue transglutaminase expression and activity in placenta.

Nicola J Robinson1, Jocelyn D Glazier, Susan L Greenwood, Philip N Baker, John D Aplin.   

Abstract

Tissue transglutaminase (tTG) expression, distribution and activity were examined in human placenta and derived cells. Immunochemical techniques and RT-PCR were used to demonstrate tTG protein and mRNA in stromal cells and trophoblast in first trimester and at term, with higher levels later in pregnancy. Decidual cells also produce tTG. The data were confirmed using primary cultures of trophoblast, fibroblasts and decidual stromal cells. Substrate incorporation studies indicated tTG activity in association with fibroblast extracellular matrix and the syncytial microvillous membrane (MVM), where several target polypeptides could be observed. tTG is a major autoantigen in Coeliac disease (CoD) which is associated with poor pregnancy outcome. tTG at the placental MVM is a plausible target of maternal autoantibody action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16338459     DOI: 10.1016/j.placenta.2005.01.008

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  9 in total

1.  The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia.

Authors:  M Cheng; P He; J Fu
Journal:  J Hum Hypertens       Date:  2016-05-12       Impact factor: 3.012

Review 2.  Female Infertility and Serum Auto-antibodies: a Systematic Review.

Authors:  Alban Deroux; Chantal Dumestre-Perard; Camille Dunand-Faure; Laurence Bouillet; Pascale Hoffmann
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

3.  Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.

Authors:  Chen Liu; Wei Wang; Nicholas Parchim; Roxanna A Irani; Sean C Blackwell; Baha Sibai; Jianping Jin; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-11-04       Impact factor: 10.190

Review 4.  Celiac disease and obstetrical-gynecological contribution.

Authors:  Giovanni Casella; Guido Orfanotti; Loredana Giacomantonio; Camillo Di Bella; Valentina Crisafulli; Vincenzo Villanacci; Vittorio Baldini; Gabrio Bassotti
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

Review 5.  Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase.

Authors:  Chen Liu; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2017-08-01       Impact factor: 2.689

6.  Maternal celiac disease autoantibodies bind directly to syncytiotrophoblast and inhibit placental tissue transglutaminase activity.

Authors:  Naheed Anjum; Philip N Baker; Nicola J Robinson; John D Aplin
Journal:  Reprod Biol Endocrinol       Date:  2009-02-19       Impact factor: 5.211

7.  Altered Esophageal Mucosal Structure in Patients with Celiac Disease.

Authors:  María Inés Pinto-Sánchez; Fabio D Nachman; Claudia Fuxman; Guido Iantorno; Hui Jer Hwang; Andrés Ditaranto; Florencia Costa; Gabriela Longarini; Xuan Yu Wang; Xianxi Huang; Horacio Vázquez; María L Moreno; Sonia Niveloni; Premysl Bercik; Edgardo Smecuol; Roberto Mazure; Claudio Bilder; Eduardo C Mauriño; Elena F Verdu; Julio C Bai
Journal:  Can J Gastroenterol Hepatol       Date:  2016-02-29

8.  Celiac Disease and Pregnancy Outcomes in Patients with Gestational Diabetes Mellitus.

Authors:  Maria Grazia Dalfrà; Gloria Giovanna Del Vescovo; Silvia Burlina; Ilaria Baldan; Silvia Pastrolin; Annunziata Lapolla
Journal:  Int J Endocrinol       Date:  2020-10-16       Impact factor: 3.257

Review 9.  The Role of Early Programming and Early Nutrition on the Development and Progression of Celiac Disease: A Review.

Authors:  Rafael Martín-Masot; Javier Diaz-Castro; Jorge Moreno-Fernandez; Víctor Manuel Navas-López; Teresa Nestares
Journal:  Nutrients       Date:  2020-11-08       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.